TMDX · TransMedics Group, Inc. · Documents

Jul 29

Current report 8-K Events of Jul 26

Completed an acquisition or sale of assets

Jul 2

Current report 8-K Events of Jun 27

Completed an acquisition or sale of assets

May 28

Current report 8-K Events of May 23

Shareholder vote results

May 2

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $96.85M ▲ 133.1% Net income $12.2M Diluted EPS $0.35

Apr 30

Earnings call

Q1 2024 earnings call

Apr 30

Current report 8-K

Financial results

Apr 10

Proxy statement DEF 14A Meeting May 23, 2024

Proxy statement

Apr 10

Annual report to holders ARS

Annual report to holders

Apr 10

Proxy statement DEFA14A

Proxy statement

Mar 12

Current report 8-K Events of Mar 8

Completed an acquisition or sale of assets

Feb 27

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $241.62M ▲ 158.5% Net loss $25.03M Diluted EPS -$0.77

Feb 26

Earnings call

Q4 2023 earnings call

Feb 26

Current report 8-K

Financial results

Feb 6

Current report 8-K Events of Feb 2

Completed an acquisition or sale of assets

Jan 29

Current report 8-K Events of Jan 25

Completed an acquisition or sale of assets

Jan 2

Current report 8-K Events of Dec 29

Completed an acquisition or sale of assets

Dec 19

Current report 8-K Events of Dec 18

Completed an acquisition or sale of assets

Nov 13

Current report 8-K Events of Nov 9

Entered into a material agreement, Completed an acquisition or sale of assets

Nov 8

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $66.43M ▲ 158.7% Net loss $25.42M Diluted EPS -$0.78

Nov 6

Earnings call

Q3 2023 earnings call

Nov 6

Current report 8-K

Financial results

Sep 22

Current report 8-K Events of Sep 21

Completed an acquisition or sale of assets

Sep 12

Current report 8-K Events of Sep 7

Completed an acquisition or sale of assets

Sep 5

Current report 8-K Events of Sep 1

Completed an acquisition or sale of assets

Aug 16

Current report 8-K

Regulation FD disclosure

Aug 4

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $52.47M ▲ 155.7% Net loss $1M Diluted EPS -$0.03

Aug 3

Earnings call

Q2 2023 earnings call

Aug 3

Current report 8-K

Financial results

Jun 29

Current report 8-K Events of Jun 23

Entered into a material agreement

May 26

Current report 8-K Events of May 25

Director or officer change, or executive pay, Shareholder vote results

May 11

Current report 8-K Events of May 8

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity

May 9

Current report 8-K Events of May 8

Entered into a material agreement

May 4

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $41.55M ▲ 161.7% Net loss $2.64M Diluted EPS -$0.08

May 1

Earnings call

Q1 2023 earnings call

May 1

Current report 8-K

Financial results

Apr 12

Proxy statement DEF 14A

Proxy statement

Apr 12

Annual report to holders ARS

Annual report to holders

Apr 12

Proxy statement DEFA14A

Proxy statement

Feb 27

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $93.46M ▲ 208.8% Net loss $36.23M Diluted EPS -$1.23

Feb 24

Current report 8-K Events of Feb 20

Director or officer change, or executive pay

Feb 22

Earnings call

Q4 2022 earnings call

Feb 22

Current report 8-K

Financial results

Nov 4

Current report 8-K Events of Nov 2

Charter or bylaw amendment, or fiscal year change

Nov 4

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $25.68M ▲ 378.3% Net loss $7.43M Diluted EPS -$0.25

Nov 3

Earnings call

Q3 2022 earnings call

Nov 3

Current report 8-K

Financial results

Aug 8

Current report 8-K Events of Aug 4

Other events

Aug 3

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $20.52M ▲ 151.1% Net loss $11.52M Diluted EPS -$0.41

Aug 3

Registration statement S-3ASR

Registration statement

Aug 1

Earnings call

Q2 2022 earnings call